Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now let's hope GNPH does well...
I think now that these lawsuits are over the could be a dividend, as once promised, for the pre-merger shareholders. Let's hope LTUS and GHII do better so that these assets GNPH owns become worth enough to pay out a nice dividend.
I am positive for the future now that these legal matters are out of the way. Just think of all the positives:
- Q2 results on the way
- news on uplisting
- new drugs to follow (within a few months?)
- recent acquisition of Hongrui
I hope Carl gives us his opinion.
From last 10q report I gather that we already meet that demand?
Total shareholders' equity $ 97,421,482
BigGreen: The pdf-document says:
Market value of publicly held shares or
Market value of publicly held shares and
stockholders’ equity
Could it be GNPH meets the second form of this demand?
(I don't really know what the stockholders'eauity of GNPH is...)
The 10Q will be out around Feb 15th that is 6 weeks after Q2 ends.
But to be honest I don't know if everything else is okay. There are a lot of demands a company has to meet before it can apply for uplisting. Do we meet them all, I don't know. I hope so and I am (almost) sure we will before the year 2009 is over.
These guys are reconsidering their goal (in a positive way) for GNPH I guess . . .
http://breanmurraycarret.com/pdf/ResearchUniverse.pdf
Wow this is great news. Congrats everyone here! Now let's hope outside investors pick it up also...
BigGreen:
I don't know how about putting that application in. I have posted some links last year where maybe we could find that info. Want to help me search? Read the lnks in post 4789 AND 4790. I haven't found the answer yet...
...for a total purchase price of RMB110 million (approximately $16.1 million) consisting of RMB66 million in cash (approximately US$9.6 million) and 643,651 shares of the Company's common stock...
So that means that 643,651 shares are valued at 16.1 - 9.6 = 6.5 millon dollar. That's $ 10. Good start for now...
and buying . . . 22 new medicines.
Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines
LAIYANG, China, Jan. 29 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that Laiyang Jiangbo Pharmaceutical Co., Ltd. ("Laiyang"), a wholly-owned subsidiary of the Company, entered into an Assets Transfer Contract (the "Contract") with Shandong Chinese Traditional Medicine College (the "Medicine College") and Hongrui Pharmaceuticals, Ltd. ("Hongrui"), a wholly-owned subsidiary of the Medicine College, pursuant to which Laiyang will purchase the majority of the assets owned by Hongrui, including all tangible assets, including without limitation, all manufacturing and office buildings, land, equipment and inventories and all rights to manufacture and distribute Hongrui's 22 Traditional Chinese Medicines ("TCM"), for a total purchase price of RMB110 million (approximately $16.1 million) consisting of RMB66 million in cash (approximately US$9.6 million) and 643,651 shares of the Company's common stock. Because the current fair market value share price is approximately US$2.6 million; the Company has valued the transaction at approximately US$12.2 million.
The purchase will be consummated in stages following the receipt by the parties of all required regulatory approvals including the approval of the Shandong Province Food and Drug Administration ("SFDA") and the approval of the Shandong State Owned Assets Administration Department. As of January 23, 2009, this transaction has been approved by the Shandong State Owned Assets Administration Department and certain assets were transferred to Laiyang. Pursuant to the terms of the Contract, the purchase consideration will be paid to the Medicine College as follows: RMB20 million (approximately US$2.9 million) of the purchase price will be paid to the Medicine College in cash within one month of the initial transfer of assets to Laiyang (by February 23, 2009). Another RMB46 million (approximately US$6.7 million) of the purchase price will be paid to the Medicine College in cash once the SFDA transfers the owner registration of Hongrui's 22 TCM products from Hongrui to Laiyang. The Contract provides that in the event that the SFDA does not approve the transfer of the ownership of Hongrui's 22 TCM products from Hongrui to Laiyang that Laiyang may cancel the Contract and rescind any transfers and payments previously consummated or made. The remaining RMB44 million of the purchase price will be paid to the Medicine College in the form of 643,651 newly issued shares of Genesis common stock within one year of the date of the execution of the Contract.
Hongrui Pharmaceuticals, Limited
Hongrui was founded in 1971 as an affiliate business of the Medicine College. It has a 33,350 square meter production and distribution facility located in the eastern part of Laiyang city which includes a 5,330 square meter plant and a 1,880 square meter warehouse. Hongrui has approximately 120 employees. Hongrui's revenue for 2007 was RMB113 million. Hongrui's revenue for the eight months ended August 31, 2008, was RMB 80.6 million, with an over 10% net profit margin. Laiyang will acquire Hongrui's production and distribution facility, equipment and inventories.
Hongrui produces a number of traditional Chinese medicines in tablet, capsule, syrup, pill and cream form which are widely used to cure gynecologic diseases, fevers, colds and coughs, pediatric diseases, and for daily health care. Hongrui also developed a drug used to treat bone and bone marrow inflammations for which it owns the intellectual property rights and is the exclusive manufacturer in China.
Hongrui groups its drugs into series:
-- Gynecology series - Motherwort Herb electuary, Motherwort Herb granules and Yimu granules to help ease labor pains
-- Laiyang Pear series - Laiyang Pear syrup and pulps to control coughs arising from various factors
-- Cold series - Syrup and granules, and Radix Isatidis granules, to help reduce fevers and control coughs
-- Pediatric series - Oral liquids to control children's coughs, asthma and fever
-- Traditional Cure series - Liuweidihuang pills to help improve memory, Aplotaxis Carminative pills for upset stomachs, and pills for a variety of liver and stomach ailments
Acquisition by Genesis
The acquisition of Hongrui by Laiyang will increase Genesis' product portfolio from 6 to 28 products during a time when the Chinese SFDA is tightening its standards and slowing down its approval process for new drugs. A larger number of TCM products will help increase the Company's presence in the OTC drug market and help balance Genesis' OTC sales with its sales of prescription drugs.
After the asset transfer is complete, Genesis will begin manufacturing, labeling and distributing the TCM products it purchased from Hongrui under its own brand name "Jiangbo." As a first phase, Genesis selected 11 Hongrui products to produce and distribute. These 11 TCM drugs have had the highest sales volumes and profit margins of all of Hongrui's products.
"After months of due diligence, we are pleased to enter into a purchase agreement with the Medicine College through which we will acquire Hongrui. Genesis is accelerating its growth by acquiring profitable products from Hongrui which we will manufacture and then distribute through our sales network. We estimate that this acquisition will increase Genesis' revenues by approximately RMB150 million, and net income by approximately RMB24 million, in the twelve months after closing," said Mr. Wubo Cao, CEO of Genesis. "We plan to integrate Hongrui's production and sales into our existing manufacturing and sales network. We believe that our product mix after this acquisition will enable us to better meet the demands of the growing OTC drug market in China."
About Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, and granule form.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the acquisition of Hongrui. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
Contact:
Genesis Pharmaceuticals CCG Investor Relations, Inc.
Enterprises, Inc. Mr. Crocker Coulson, President
Ms. Elsa Sung, CFO Phone: (646) 213-1915
Phone: (954) 727-8435 E-mail: crocker.coulson@ccgir.com
E-mail: elsasung@jiangbo.com http://www.ccgirasia.com
http://www.genesispharmaceuticals.com
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
-0- 01/29/2009
/CONTACT: Genesis Pharmaceuticals Enterprises, Inc., Ms. Elsa Sung, CFO, +1-954-727-8435, elsasung@jiangbo.com; CCG Investor Relations, Inc., Mr. Crocker Coulson, President, +1-646-213-1915, crocker.coulson@ccgir.com/
/Web site: http://www.genesispharmaceuticals.com /
(GTEC GTEC.OB)
You are receiving this transmission from PR Newswire on behalf of the issuer of the information contained in this email. If you would like to stop receiving information of this nature via email for this issuer, click here, for auto-removal.
Happy New Year !
Thanks for the summary I think it is a very good one! Best wishes to all.
Thanks. You would think they would bring out a PR earlier because it is a positive thing? We'll see.
If GNPH has actually bought back their own shares how would we know? Do they have to make a filing for that with the SEC ?
Or are they not buying because they think the shares will be even cheaper?
We'll see in 2009
Best wishes for all...
Only 2 days left and yet another quarter has ended. 2nd quarter of fiscal year 2009 that is. Reports on it should be out around Feb 15th or so. Guess that will be the first occasion there will be news out on GNPH...
Still no news on the "lawsuit". Guess that is good news then, else the filers would have brought out a PR if it went well for them...
A little early:
Merry Christmas all!!
Let's go!
Am I stupid that I am not buying any more shares?
Or better safe than sorry?
Long: Thanks for sharing.
Don't we deserve it ?
Are we sitting on dead money or what?
What should be the next occasion we'll get some news?
The results on the 2nd quarter?
Or maybe news on uplisting before the end of 2008?
A new drug out on the market?
An end to these lawsuits?
...
Because?
a. Lawsuits are being settled at the moment.
b. Lawsuits have been cancelled.
c. We'll all get rich, with or without pending lawsuits.
d. none of the above but because . . .
Yes, you are right on that, but the sooner these lawsuits will be out of the way the better. I don't know if a company can uplist when it is involved in a law suit? Or does GNPH have to deal with this first before we can uplist?
It still is strange that a dividend was promised but GNPH never said anything about it everafter...
Genesis Technology Group, Inc. (OTC BB: GTEC), explained to its shareholders how it envisions reaching goals of profitability and stock price enhancement. Outlined in a "State of the Company" letter posted on the Company website, dated Memorial Day 2005, Genesis's CEO addressed the restructuring of its subsidiaries, operations and revenue sources.
Key points in the "State of the Company" letter include: (1) status of its core subsidiary Chorry Technology Development Company, Ltd.; (2) establishment of the new Genesis Hong Kong OEM Direct branch office; (3) closing its majority-owned subsidiary Extrema LLC; (4) expansion of its relationship with client Gulf South Forest Products, Inc.; (5) status of its business development division; (6) discussion about the current and future stock price; and (7) planning for an Annual Stockholders' Meeting. The entire letter may be viewed at http://www.genesis-technology.net/ceo_letter.asp
Source:http://findarticles.com/p/articles/mi_pwwi/is_/ai_n13646937
What a shame these webpages aren't cached somewhere
Wasn't there supposed to be a hearing on the counter claim on Dec. 1st ?
Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH - News; "Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, was granted leave by the American Arbitration Association ("AAA") to amend its counterclaims and add claims for defamation and breach of contract in a contractual dispute with Capital Research Group Partners, Inc. and Capital Research Group, Inc. ("CRG&P"). The hearing date for the arbitration is set for December 1, 2008 in the AAA offices in Miami, Florida.
http://biz.yahoo.com/prnews/081031/cnf033.html?.v=3
Curious what the result will be....
Mr. Wolfson did do something good with the money:
http://fundrace.huffingtonpost.com/neighbors.php?type=emp&employer=Pacific+Rim+Consultants%2C+Inc.
{Copy & paste the link, else it doesn't work ?!)
Now lets distribute the rest of GTEC's assets to their rightfull owners.
Carl,
As you know I have been a longtime shareholder of GTEC. I don't think all the employee's/directors of GTEC had our best interest in mind. I do think the business-model could have been a great succes, maybe if others had been in charge. By gaining parts of the companies they helped they where creating shareholder value. That value hasn't been turned over too the shareholders (yet). For that part I agree. It partially could have been if the assets (shares of GHII and LTUS) were sold by GNPH for a good price in the future.
I really don't know what value we should give to a pre-merger share or how we can get anything out of that now.
But I also think the new GNPH could bring even bigger shareholder value. And I know that these law-suits/cases aren't doing GNPH any good now. Either way I am fearing that my invested money will remain dead for a long time.
Would you have voted for or against if you had been asked?
What would you think would be a fair value of a pre-merger share and thus a fair amount to be demanded by CRG / China West / whoever ?
Where do you get all that info, I had never heard of Lizzie Gardens?
What does "get the shaft" mean?
Is it legally impossibe for China West etc to get too the former directors directly instead of going through GNPH?
Let's give them some more attention, here we go:
Press Release Source: China West II
China West II Announces Correction and Update to Conference Call Details Regarding Suit Against Genesis Pharmaceuticals
Friday November 28, 3:13 pm ET
MIAMI, Nov. 28 /PRNewswire-FirstCall/ -- China West II yesterday announced it has filed an additional law suit in Miami Dade County, Florida state court against Genesis Pharmaceuticals (OTC Bulletin Board: GNPH - News), (Genesis) f/n/a Genesis Technology Group, Inc. (GTEC) and Genesis Equity Partners II (GEP II) for GEP II's failure to pay a $190,000 promissory note that became due in August 2008 and for Genesis failure to pay its guarantee of 75% of the amount due under the note.
Due to circumstances beyond our control, the conference call which had been scheduled for today, November 28, has been canceled and rescheduled. Capital Research Group will hold a shareholder caucus, via teleconference on November 29, 2008 at 5 pm EST. The purpose of this teleconference and online gathering will be to discuss the prospect of potential shareholder litigation against Genesis Pharmaceutical Enterprise, GTEC Current and Past Directors and GTEC Holdings. The telephone number for the conference is 1-866-212-0875 and the pass code is 161768.
China West II is represented by Jeffrey Tew, Esq., Tew Cardenas, 15th Floor Four Seasons Tower, 1441 Brickell Avenue, Miami, FL 3331. Genesis is represented by Benjamin Olive, Esq., Olive & Associates, 2438 E. Las Olas Blvd., Fort Lauderdale, FL 33301. China Wind Systems traded as high as $6.00.
Certain statements set forth in this press release constitute 'forward- looking statements.' Forward-looking statements including, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words 'estimate,' 'project,' 'intend,' 'forecast,' 'anticipate,' 'plan,' 'planning,' 'expect,' 'believe,' 'will likely,' 'should,' 'could,' 'would,' 'may' or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
Source: China West II
http://biz.yahoo.com/prnews/081128/clth006.html?.v=101
It is getting boring and I hope these things will be over and done before 2009.
http://biz.yahoo.com/prnews/081127/clth006.html?.v=101
Press Release Source: China West II
China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
Thursday November 27, 1:17 pm ET
MIAMI, Nov. 27 /PRNewswire/ -- China West II today announced it has filed an additional law suit in Miami Dade County, Florida state court against Genesis Pharmaceuticals (OTC Bulletin Board: GNPH - News), (Genesis) f/n/a Genesis Technology Group, Inc. (GTEC) and Genesis Equity Partners II (GEP II) for GEP II's failure to pay a $190,000 promissory note that became due in August 2008 and for Genesis failure to pay its guarantee of 75% of the amount due under the note.
GEP II borrowed $190,000 from China West II to complete the China Wind Systems (OTC Bulletin Board: CWSI - News) reverse merger and Genesis guaranteed payment of 75% of all sums due under the note. GEP failed to pay the $190,000 promissory note when it was due and Genesis failed to pay its guarantee. Genesis also failed to dividend the CWSI stock to all of the GEP II partners as outlined in the GEP II operating agreement. China West II has also filed a separate $6.7 million arbitration against Genesis with the American Arbitration Association for Genesis' failure to distribute to China West II its share of the CWSI stock.
Genesis Equity Partners II (GEP II) was formed in 2007 to complete the private to public reverse merger program for China Wind ("Green Power"). GTEC owned 51%, China West owned 24.5% and Joshua Tan, a director of Genesis, owned 24.5% of GEP II. Green Power completed the private to public process in November 2007.
Neither Genesis shareholders nor China West II received their rightful share benefit. Greenview Capital, the same firm that arranged the Genesis financing, received 2,420,204 shares and Cawston Enterprises received 2,866,570 of CWSI as well.
Pacific Rim Consultants Inc., whose officers are Justin A. Wolfson, Caeli R. Wolfson Widger, Jonathan A. Wolfson, and Gregory T. Wolfson, received 3,089,753 shares in China Wind Systems or Green Power. Gary L Wolfson is the registered agent for Pacific Rim Consultants as well as former Genesis Chairman of the Board and CEO and CEO of Genesis Holdings.
Furthermore, in addition to the arbitration and current litigation cases, Capital Research Group will hold a shareholder caucus, via teleconference on November 28, 2008 at 12 pm EST. The purpose of this teleconference and online gathering will be to discuss the prospect of potential shareholder litigation against Genesis Pharmaceutical Enterprise, GTEC Current and Past Directors and GTEC Holdings. The telephone number for the conference is 1-888-296-6828 and the pass code is 516928.
China West II is represented by Jeffrey Tew, Esq., Tew Cardenas, 15th Floor Four Seasons Tower, 1441 Brickell Avenue, Miami, FL 3331. Genesis is represented by Benjamin Olive, Esq., Olive & Associates, 2438 E. Las Olas Blvd., Fort Lauderdale, FL 33301. China Wind Systems traded as high as $6.00.
Source: China West II
-* Happy thanksgiving to y'all *-
Boy, nice jump today.
OTCBB stocks aren't really dead
Transcript of Conference Call:
Genesis Pharmaceuticals Enterprises, Inc. (GNPH.OB)
F1Q09 (Qtr End 09/30/08) Earnings Call Transcript
November 17, 2008, 10:00 am ET
Executives
Crocker Coulson - President, CCG
Xu Haibo - COO
Elsa Sung - CFO
Analysts
Louis Mark
Lu Jeans
Jen Hue
Angel Lew
Peter Styris
Presentation
Operator
Good day, ladies and gentlemen, and welcome to the Genesis Pharmaceuticals’ Earnings Conference Call. My name is Jessica, and I will be your coordinator for today. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of this conference. (Operator Instructions). As a reminder, this conference is being recorded for replay purposes.
I would now like to turn the presentation over to your host for today’s call, Mr. Crocker Coulson, President of CCG. Please proceed, sir.
Crocker Coulson
Hi. Thank you very much, operator. Good morning everybody, and welcome to Genesis Pharmaceuticals’ first quarter of fiscal 2009 earnings conference call. I am Crocker Coulson, and with us today on the call are Mr. Xu, Genesis Pharmaceuticals’ Chief Operating Officer, and also the company’s Chief Financial Officer, Ms. Elsa Sung.
Before I turn this call over to company’s management, I’d like to remind our listeners, in this call management’s prepared remarks contain forward-looking statements which are subject to risks and uncertainties, and management may make additional forward-looking statements in response to your questions.
Therefore, the company claims the protection for forward-looking statements that’s contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from those discussed today and, therefore, we’d like to refer you to a more detailed discussion of these risks and uncertainties in the company’s filings with the SEC.
In addition, any projection as the company’s future performance represent management’s estimates as of today, November 17th, 2008, and Genesis Pharmaceuticals assumes no obligation to update these projections in the future as market conditions change.
It’s now my pleasure to turn the call over to Mr. Xu.
Xu Haibo
Thank you, Crocker. [Foreign Language].
Let me translate Mr. Xu. Thank you all. Welcome everyone, and thank you for joining us today for our first quarter of fiscal year 2009 earnings conference call. We are happy to talk that Genesis Pharmaceuticals achieved a good start to the new fiscal year. We continued the strong growth momentum of our overall base and added Radix Isatidis Dispersible Tablets to our product portfolio.
This makes us confident about our performance in the year ahead. During the course of this conference call we look forward to discussing our past operational and financial results and our outlook for the 2009 fiscal year, along with answering your questions. Thank you.
Crocker Coulson
Thank you very much, Mr. Xu and thank you [Ms. Xue]. Next, we are going to turn the call over to the company’s Chief Financial Officer Ms. Elsa Sung, and she is going to provide an update on Genesis’ Q1 operations and financial results. Elsa?
Elsa Sung
Thank you. Crocker. Once again, welcome everybody, and thank you for joining us today for our first quarter of fiscal year 2009 earnings conference call. We are pleased to share with you that Genesis Pharmaceuticals achieved strong financial results for the quarter ending September 30, 2008.
Our revenue was $27.6 million, up 65.9% from the corresponding quarter ending September 30, 2007. Gross profit was $21.8 million with a gross margin of 79.1%, up 81.3% from the corresponding quarter ending September 30, 2007.
Continues a few pages, click the link...
http://seekingalpha.com/article/106883-genesis-pharmaceuticals-enterprises-inc-f1q09-qtr-end-09-30-08-earnings-call-transcript?source=email
Thanks for update with that info!
Read previous message first, I was too late too edit it...
If 25% of that 138 million will be net income that generates $ 34.5 million! Current market cap. of GNPH is approx.: pps $5 x 10 million shares = $ 50 million !
@abh3vt: Your remark about Q1 being the slowest was right, I've noticed that too.
If we look at FY 2008: Q1 revenue 16.6 million Q2, 3, 4 were approx. 27 million. Total fiscal year was approx. 99 million
If that difference occurs also in FY 2009 that would mean the following:
Q1 27.6 million let's assume 10 million extra in the next quarters (just like fiscal year 2008)
Q2, 3, 4 each 37 million, that makes a total for fiscal year 2009 of $ 138 million, just like predicted by the company!!
Let's sum it up:
1. CRG claims $13 million, we will know more after Dec. 1st when 1st hearing has been held.
2. China West I/II claims a total sum of $13 million. First hearing to be held .... unknown (to me) ?
Has someone here listened / participated in the conference call? Want to share some information?
PR on the numbers, this is nice to read:
http://finance.yahoo.com/news/Genesis-Pharmaceuticals-prnews-13590734.html
Now the only thing we need is an exact date for the uplisting to take place. Will it happen this year? May take a little extra time if I read this:
"Regarding corporate governance, we are in the process of selecting and engaging a professional consulting company to help us meet the requirements of the Sarbanes-Oxley Act of 2002. The improvements we want to bring to our corporate governance are guided by the requirements for applying to a senior U.S. stock exchange. We hope to apply to a senior U.S. stock exchange in the near future in order to increase visibility and liquidity for our shares, and value for our shareholders."
Now made a PR out of the sharebuyback program:
"While recognizing that share prices for most listed companies have recently declined, we believe that recent prices for Genesis' shares do not reflect the true value of our company," said Mr. Wubo Cao, Chief Executive Officer of Genesis. "Our board of directors authorized the share repurchases to show support for our company and confidence in its long term financial performance. We view these share repurchases as part of our ongoing commitment to increase shareholder value."
Very good!!! Strong point!!!
http://finance.yahoo.com/news/Genesis-Pharmaceuticals-Plans-prnews-13590733.html
At least revenues are well on schedule to reach 100+ million fiscal year 2009. I think first quarter is the weakest every year?
Numbers are out:
http://biz.yahoo.com/e/081114/gnph.ob10-q.html
An increase (+80%!!) in revenues which leads to a decrase in net income?! What to think of that?
When will we see this happen:
EPS $ 0.32 (this quarter) x 4 (for whole year) = $ 1.28
PE 20
when listed on Nasdaq PPS would be 20 x 1.28 = $ 25.60
Monday 17th Nov. 09:00 conference call on Q1 results.
@BigGreen101: You're welcome
@_bbb_: That's why I brought it up again, I hope it is leaving the station for real this time. I think you need it too. Other Promising Long Term's aint doing so great either I guess?
It is like Obama says: It's time for change! Better future ahead for us shareholders in GNPH?